Among these, larotrectinib has been used in a patient with refractory pediatric secretory breast cancer with ETV6-NTRK3 fusion [52] and showed a marked and durable antitumor effect in 55 patients with NTRK fusion-positive cancer. Here, NTRK3 is linked to cancer.